Online inquiry

IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4686MR)

This product GTTS-WQ4686MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4686MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7343MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ8633MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ8926MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ7498MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ15191MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ1821MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1785MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ3266MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW